Ocuvia

Company Overview

Snapshot

Founded in March 2026, Ocuvia operates with 1–10 employees. The company is currently in its pre-funding stage, focusing on consolidating its ophthalmology activities and exploring a potential U.S. listing and capital raise during 2026.

Business overview

Ocuvia is an ophthalmology-focused venture formed by BioLight Life Sciences, consolidating the activities of OphRx and ViSci. The company develops eye-drop-based therapies using a platform to improve ocular drug delivery to the front of the eye and the retina, alongside the D-EYE sub-conjunctival implant for controlled, sustained release of active ingredients for glaucoma. Ocuvia serves the medical devices and medical treatment & therapeutics sectors within the broader health tech & life sciences industry.

Company Intelligence Q&A

What is Ocuvia's primary focus?

Ocuvia is an ophthalmology-focused venture dedicated to developing drug delivery solutions and implant-based glaucoma therapies.

When was Ocuvia founded?

Ocuvia was founded in March 2026.

What is the strategic intent behind Ocuvia's formation?

Ocuvia was formed by BioLight Life Sciences to consolidate the activities of two portfolio companies, OphRx and ViSci, aiming to streamline R&D, business development, and fundraising under a single management team.

What products or technologies is Ocuvia developing?

Ocuvia is developing eye-drop-based therapies for improved ocular drug delivery and the D-EYE sub-conjunctival implant for sustained release of glaucoma treatments.

What are Ocuvia's future plans regarding funding and market presence?

Ocuvia is examining a potential U.S. listing and capital raise during 2026 to support its consolidated operations and development efforts.